MeiraGTx Holdings (MGTX) Share-based Compensation (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Share-based Compensation came in at $5.6 million in Q4 2025, down 75.65% YoY from $22.9 million in Q4 2024, and up 18.4% on a QoQ basis from $4.7 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Share-based Compensation (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Share-based Compensation data on file, last reported at $5.6 million in Q4 2025.
- Quarterly Share-based Compensation fell 75.65% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.2 million (down 8.72% YoY) and the FY2025 annual result came in at $24.7 million, down 1.95% from the prior year.
- Share-based Compensation improved to $5.6 million in Q4 2025, from $4.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $22.9 million in Q4 2024 to a low of $2.1 million in Q1 2025.
- A 5-year average of $6.6 million and a median of $5.7 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation soared 42.83% — and 2025, when it sank 75.65%.
- Tracing MGTX's Share-based Compensation over 5 years: stood at $7.1 million in 2021, then dropped by 4.61% to $6.8 million in 2022, then slipped by 0.59% to $6.8 million in 2023, then jumped by 237.78% to $22.9 million in 2024, then slumped by 75.65% to $5.6 million in 2025.
- The last three Share-based Compensation figures came in at $5.6 million (Q4 2025), $4.7 million (Q3 2025), and $5.7 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 7.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.53 Mn |
| Dec 31, 2025 | 5.60 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 8.06 Mn |
| Mar 31, 2025 | 8.02 Mn |
| Dec 31, 2024 | 6.12 Mn |
| Sep 30, 2024 | 8.27 Mn |
| Jun 30, 2024 | 8.34 Mn |
| Mar 31, 2024 | 8.48 Mn |
| Dec 31, 2023 | 6.96 Mn |
| Sep 30, 2023 | 8.31 Mn |
| Jun 30, 2023 | 8.31 Mn |
| Mar 31, 2023 | 8.23 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | 6.97 Mn |
| Jun 30, 2022 | 7.30 Mn |
| Mar 31, 2022 | 6.97 Mn |
| Dec 31, 2021 | 7.13 Mn |
| Sep 30, 2021 | 6.14 Mn |
| Jun 30, 2021 | 6.24 Mn |